Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Discover why Johnson & Johnson is a top stock pick for income investors in 2025 with strong sales growth and promising earnings outlook.
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the ...
J&J Tops Quarterly Profit Estimates on Cancer Drug Sales
Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...
Wall Street Lunch: AI Project Stargate A Go
Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data ...
Balanced Expectations Amid Challenges and Opportunities for Johnson & Johnson: Hold Rating Issued
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Biden insisted he didn’t sign executive order just weeks after doing so, Speaker Johnson reveals
House Speaker Mike Johnson revealed President Biden insisted to him he hadn’t issued an executive order freezing liquid ...
Morningstar8d
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Medical-technology and drug company's 2025 sales outlook is below consensus Johnson & Johnson's stock ... from Dow Jones Newswires and The Wall Street Journal. Chip stocks and other AI-related ...